Initiation of Phase I Clinical Trials for MucoRice Oral Vaccine at Chiba University Hospital

Launching Phase I Clinical Trials for MucoRice

Asahikogyo Co., Ltd., headquartered in Minato, Tokyo, has exciting news regarding its innovative oral rice vaccine, MucoRice. The Phase I clinical trials for MucoRice are to commence in September 2026, conducted at the Clinical Pharmacology Center of Chiba University Hospital, under the stewardship of Professor Seiji Ohtori.

In collaboration with Japan's National Center for Global Health and Medicine, Asahikogyo has been advancing its mission to develop MucoRice as part of an initiative funded under the Vaccine and Therapeutics Development project. This project aims to demonstrate the mucosal immune induction effects of MucoRice-CTB_19A in humans, coupled with developing a novel room-temperature stable oral vaccine platform to combat respiratory infections.

For this endeavor, Asahikogyo has been working closely with Professor Hiroshi Kiyono, a prestigious figure in mucosal vaccine research at Chiba University. The company has secured the responsibility for managing the manufacturing process of MucoRice-CTB19A, utilizing its expertise in environmental control from its closed-type plant factories to ensure the vaccine's consistent production.

A standout feature of MucoRice is its remarkable stability at ambient temperatures. Unlike conventional vaccines requiring stringent cold chain logistics for storage and distribution, MucoRice is designed to be utilized effectively in developing countries where access to refrigeration is limited, and during times of disaster when power sources may be unreliable. This unique capability makes it a revolutionary solution in the world of immunization.

Asahikogyo's commitment to this project goes beyond simple production. The company is determined to continue its cooperative research with Chiba University, focusing on developing a stable production process for MucoRice using its advanced agricultural technologies.

In addition to the ongoing clinical trials, more information about MucoRice and its journey can be found in the company’s releases and updates.

For those interested in the broader implications of this research, Chiba University has included information on the inauguration of its Clinical Pharmacology Center, the only facility in the prefecture designated for Phase I trials.

About Asahikogyo Co., Ltd.

Founded in 1925, Asahikogyo has dedicated itself to creating optimal environments based on the sciences of air, water, and heat. The company specializes in installation projects and manufacturing and selling equipment for a variety of sectors. From designing precision environmental control systems for semiconductor and LCD manufacturers to developing drying devices for printing and coating machines, Asahikogyo aims to create comfortable environments and optimal spaces for various industries.

For more information, visit Asahikogyo's website.